Defence Therapeutics Stock Buy Hold or Sell Recommendation
| DTCFF Stock | USD 0.41 0.00 0.00% |
Assuming the 90 days horizon and your complete indifference towards market risk, our recommendation regarding Defence Therapeutics is 'Hold'. Macroaxis provides Defence Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding DTCFF positions.
Check out Defence Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Defence and provide practical buy, sell, or hold advice based on investors' constraints. Defence Therapeutics. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census.
Defence |
Execute Defence Therapeutics Buy or Sell Advice
The Defence recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Defence Therapeutics. Macroaxis does not own or have any residual interests in Defence Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Defence Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Defence Therapeutics Trading Alerts and Improvement Suggestions
| Defence Therapeutics has some characteristics of a very speculative penny stock | |
| Defence Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Defence Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Defence Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Defence Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Defence to invest in growth at high rates of return. When we think about Defence Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (7.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Defence Therapeutics has accumulated about 506.7 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
Defence Therapeutics Returns Distribution Density
The distribution of Defence Therapeutics' historical returns is an attempt to chart the uncertainty of Defence Therapeutics' future price movements. The chart of the probability distribution of Defence Therapeutics daily returns describes the distribution of returns around its average expected value. We use Defence Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Defence Therapeutics returns is essential to provide solid investment advice for Defence Therapeutics.
| Mean Return | -0.15 | Value At Risk | -2.44 | Potential Upside | 0.00 | Standard Deviation | 3.22 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Defence Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Defence Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Defence Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Defence Therapeutics' price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Defence otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 0.11 | |
σ | Overall volatility | 2.69 | |
Ir | Information ratio | -0.09 |
Defence Therapeutics Volatility Alert
Defence Therapeutics exhibits very low volatility with skewness of -0.39 and kurtosis of 15.33. Defence Therapeutics is a potential penny stock. Although Defence Therapeutics may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Defence Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Defence instrument if you perfectly time your entry and exit. However, remember that penny otcs that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Defence Therapeutics Fundamentals Vs Peers
Comparing Defence Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Defence Therapeutics' direct or indirect competition across all of the common fundamentals between Defence Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Defence Therapeutics or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Defence Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Defence Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Defence Therapeutics to competition |
| Fundamentals | Defence Therapeutics | Peer Average |
| Return On Equity | -4.15 | -0.31 |
| Return On Asset | -1.79 | -0.14 |
| Current Valuation | 60.32 M | 16.62 B |
| Shares Outstanding | 37.85 M | 571.82 M |
| Shares Owned By Insiders | 5.26 % | 10.09 % |
| Price To Book | 36.71 X | 9.51 X |
| EBITDA | (7.32 M) | 3.9 B |
| Net Income | (7.34 M) | 570.98 M |
| Cash And Equivalents | 506.7 K | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Current Ratio | 0.61 X | 2.16 X |
| Book Value Per Share | (0.03) X | 1.93 K |
| Cash Flow From Operations | (6.04 M) | 971.22 M |
| Earnings Per Share | (0.15) X | 3.12 X |
| Number Of Employees | 4 | 18.84 K |
| Market Capitalization | 143.45 M | 19.03 B |
| Total Asset | 719.67 K | 29.47 B |
| Z Score | -33.0 | 8.72 |
| Net Asset | 719.67 K |
Defence Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Defence . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Defence Therapeutics Buy or Sell Advice
When is the right time to buy or sell Defence Therapeutics? Buying financial instruments such as Defence OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Defence Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 223 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Defence OTC Stock
Defence Therapeutics financial ratios help investors to determine whether Defence OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Defence with respect to the benefits of owning Defence Therapeutics security.